Recruiting
A Study to Evaluate CC-486 in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Cancer Participants - CA055-001
Opdateret:
4 november, 2024
|
ClinicalTrials.gov
Fase
Køn
Aldersinterval
Beliggenhed(er)
Recruiting
Inclusion Criteria: - Documented diagnosis of Myelodysplastic syndrome, Acute myeloid leukemia, Multiple myeloma, Non-Hodgkin's lymphoma, Hodgkin's lymphoma or metastatic or inoperable solid tumors - Life expectancy of ≥ 3 months - Stable renal function without dialysis for at least 2 months prior to investigational product administration - Has moderate or severe hepatic impairment as defined by National Cancer Institute Organ Dysfunction Working Group criteria Exclusion Criteria: - Chemotherapy or radiotherapy within 4 weeks prior to the first day of investigational product administration - Persistent, clinically significant non-hematologic toxicities from prior therapies which have not recovered to < Grade 2 - Any condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study - History of inflammatory bowel disease, celiac disease, prior gastrectomy, gastric bypass, upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption of the investigational product and/or predispose the participant to an increased risk of gastrointestinal toxicity Other protocol-defined inclusion/exclusion criteria apply
Hvis du vil rapportere en bivirkning, kan du indberette direkte til Lægemiddelstyrelsen via hjemmesiden www.meldenbivirkning.dk
Vi anbefaler at du også kontakter BMS for at rapportere bivirkninger.
Bivirkninger og andre rapporterbare begivenheder er defineret her
Rapporter bivirkninger eller klager over produktkvalitet: Medicinsk information
466-DK-2200001